News - PharmTak, Inc.

2009
2010
2012
2014
2015
2016
2017

2017
November	Hisun obtained FDA approval for ANDA applications 204076 (Mycophenolate mofetil tablets, 500 mg) and 204077 (Mycophenolate mofetil capsules, 200 mg). These are Hisun/PharmTak joint-development products.
September	PharmTak obtained FDA approval for ANDA application 207175 (Levetiracetam extended release tablets, 500 and 750 mg).
2016
August	PharmTak submitted ANDA application 209198 for H612 (delayed release capsules).
January	PharmTak decided to cancel Series D financing, and planned for a new Series E financing.
2015
November	PharmTak submitted ANDA application 208438 for H624 (oral disintegration tablets).
August	PharmTak submitted ANDA application 208260 for H621 (tablets).
April	PharmTak closed Series D financing.
January	PharmTak closed Series C financing.
2014
December	PharmTak appointed Dr. Dean Tsao as Director of the Company. PharmTak closed Series B financing.
November	PharmTak appointed Dr. J.C. Lee as Secretary of the Board.
May	PharmTak submitted ANDA application 207175 for H605 (extended release tablets).
March	PharmTak submitted ANDA application 206892 for H603 (oral disintegration tablets).
February	PharmTak submitted ANDA application 206924 for H619 (tablets).
2012
May	ANDA applications 204076 and 204077 were submitted to the U.S. FDA for the first two joint-development products, H601 (tablets) and H602 (capsules). Hisun is the ANDA holder for these applications.
February	Pharmtak closed Series A-Extension financing.
2010
July	Pharmtak closed Series A financing.
March	PharmTak, Inc. and Zhejiang Hisun Pharmaceutical Co., Ltd. (China) established a Development, Manufacturing, and Supply Agreement for nine ANDA products for the U.S. market. PharmTak will focus on developing formulations, processing, and registration. Hisun will focus on registration, manufacturing, bioequivelancy studies, stability testing, and commercial supply.
2009
May	PharmTak appointed Dr. J.C. Lee as President, Chief Executive Officer, and Chief Financial Officer, and Robert D. Cochran as Secretary of the Board.
April	PharmTak, Inc. registered with the State of California as a California company. PharmTak appointed Dr. J.C. Lee and Dr. George J. Lee as Directors of the Company.